Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.

FDA Drug Approvals

Med Alerts

Otulfi™ (ustekinumab-aauz)

Approval Date: Sep 2024

Note: New Product

A biosimilar to Stelara, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

Zurnai® (nalmefene injection)

Approval Date: Aug 2024

Note: New Product

An opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids.

Neffy® (epinephrine nasal spray)

Approval Date: Aug 2024

Note: New Product

Indicated for the emergency treatment of type I allergic reactions, including anaphylaxis

Tezruly™ (terazosin) oral solution

Approval Date: Jul 2024

Note: New Product

Indicated for the treatment of hypertension alone or with other antihypertensive agents, and for the treatment of enlarged prostate

Zunveyl (benzgalantamine) delayed-release tablets

Approval Date: Jul 2024

Note: New Product

Indicated for the treatment of mild to moderate dementia of the Alzheimer's type

Olumiant (baricitinib) tablets

Approval Date: Jul 2024

Note: First-Time Generic

Indicated for the treatment of moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers

Kisunla (donanemab-azbt) injection

Approval Date: Jul 2024

Note: New Product

Indicated for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patient with mild cognitive impairment or mild dementia stage of disease, the population in which the treatment was initiated in the clinical trials

Qsymia® (phentermine and topiramate) extended-release tablets

Approval Date: Jun 2024

Note: First-Time Generic

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management

Stendra® (avanafil) tablets

Approval Date: Jun 2024

Note: First-Time Generic

Indicated for the treatment of erectile dysfunction

Pyzchiva® (Ustekinumab-ttwe) injection

Approval Date: Jun 2024

Note: Biosimilar

A biosimilar to Stelara; indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis

Chewtadzy (tadalafil) chewable tablets

Approval Date: Jun 2024

Note: New Product

A new chewable tablet indicated for the treatment of erectile dysfunction, and the signs and symptoms of benign prostatic hyperplasia

Descovy® (emtricitabine and tenofovir alafenamide) tablets

Approval Date: May 2024

Note: First-Time Generic

Indicated for the treatment of HIV-1 infection, in combination with other antiretroviral agents

Entresto® (sacubitril and valsartan) tablets

Approval Date: May 2024

Note: First-Time Generic

Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure

Rezenopy (naloxone hydrochloride) nasal spray

Approval Date: Apr 2024

Note: New Product

Indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression

Selarsdi (Ustekinumab-aekn) injection

Approval Date: Apr 2024

Note: Biosimilar, New Product

A biosimilar of Stelara®, this drug is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis

Risvan® (risperidone) for extended-release injectable suspension

Approval Date: Mar 2024

Note: New Product

A long-acting, atypical antipsychotic indicated for the treatment of schizophrenia

Winrevair (sotatercept-csrk) injections

Approval Date: Mar 2024

Note: Biologic, New Product

A first-in-class biologic indicated for the treatment of pulmonary arterial hypertension to increase exercise capacity and reduce the risk of clinical worsening events

Opsynvi® (macitentan and tadalafil) tablets

Approval Date: Mar 2024

Note: New Product

Indicated for the treatment of pulmonary arterial hypertension, both in patients who are treatment naïve or who are already on an ERA, PDE5 inhibitor or both

Tryvio (aprocitentan) tablets

Approval Date: Mar 2024

Note: New Product

Indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower blood pressure

Simlandi® (adalimumab-ryvk) injection

Approval Date: Feb 2024

Note: Biosimilar

A biosimilar to Humira, this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, and plaque psoriasis

Tybost (cobicistat) tablets

Approval Date: Feb 2024

Note: First-Time Generic

Indicated for the treatment of HIV-1 infection

Dilaudid (hydromorphone hydrochloride) injection

Approval Date: Feb 2024

Note: First-Time Generic

Indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate

Namzaric® (memantine and donepezil hydrochloride) extended release capsules

Approval Date: Dec 2023

Note: First-Time Generic

Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily

Zepbound (tirzepatide) injection

Approval Date: Nov 2023

Note: New Product

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity

Zituvimet (sitagliptin and metformin hydrochloride) tablets

Approval Date: Nov 2023

Note: New Product

Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes

Voquezna (vonoprazan fumarate) tablets

Approval Date: Nov 2023

Note: New Product

Indicated for erosive esophagitis and the relief of heartburn associated with erosive esophagitis

Zymfentra (infliximab-dyyb) injection

Approval Date: Oct 2023

Note: New Product

Indicated for the maintenance treatment of moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, following treatment with an infliximab product administered intravenously

Omvoh (mirikizumab-mrkz) injection

Approval Date: Oct 2023

Note: New Product

A first-in-class agent indicated for the treatment of moderate to severe ulcerative colitis

Wezlana (ustekinumab-auub) injection

Approval Date: Oct 2023

Note: Biosimilar

A biosimilar to Stelara, indicated for the treatment of moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

Velsipity (estrasimod) tablets

Approval Date: Oct 2023

Note: New Product

Indicated for the treatment of moderate to severe ulcerative colitis

Cosentyx® (secukinumab) injection for intravenous use

Approval Date: Oct 2023

Note: New Dosage or Formulation

Indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions, this drug is now available in an intravenous formulation

Bimzelx® (bimekizumab-bkzx) injection for subcutaneous use

Approval Date: Oct 2023

Note: New Product

Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Combogesic® IV (acetaminophen and ibuprofen)

Approval Date: Oct 2023

Note: Dosage or Formulation

Indicated for the short term management of mild to moderate acute pain, and the management of moderate to severe pain as an adjunct to opioid analgesics, this drug is now available in an intravenous formulation

Tofidence (tocilizumab-bavi) injection 

Approval Date: Sep 2023

Note: New Product

Indicated for the treatment of rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs)

Xeljanz (tofacitinib) oral solution

Approval Date: Sep 2023

Note: First-Time Generic

Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis

Exxua (gepirone) extended-release tablets

Approval Date: Sep 2023

Note: New Product

Indicated for the treatment of major depressive disorder (MDD), a first-in-class drug that selectively targets the serotonin 1A receptor

Lexette (halobetasol propionate) topical foam

Approval Date: Aug 2023

Note: First-Time Generic

Indicated for the topical treatment of plaque psoriasis

Onglyza (saxagliptin) tablets

Approval Date: Jul 2023

Note: First-Time Generic

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Kombiglyze® XR (saxagliptin and metformin hydrochloride) extended-release tablets

Approval Date: Jul 2023

Note: First-Time Generic

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate

RiVive (naloxone hydrochloride) nasal spray

Approval Date: Jul 2023

Note: New Product

Indicated for the emergency treatment of known or suspected opioid overdose, this drug is the second over-the-counter nonprescription opioid overdose drug approved by the FDA

Spiriva® HandiHaler (tiotropium bromide) inhalation powder

Approval Date: Jun 2023

Note: First-Time Generic

For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Katerzia® (amlodipine benzoate) oral suspension

Approval Date: Jun 2023

Note: First-Time Generic

For the treatment of hypertension and coronary artery disease

Fleqsuvy (baclofen) oral suspension

Approval Date: Jun 2023

Note: First-Time Generic

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

Diastat® AcuDial (diazepam) rectal gel delivery system

Approval Date: May 2023

Note: First-Time Generic

Indicated for the management of selected, refractory, patients with epilepsy, on stable regimens of anti-epileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity

Celontin® (methsuximide) capsules

Approval Date: May 2023

Note: First-Time Generic

Indicated for the control of absence (petit mal) seizures that are refractory to other drugs

Yuflyma (adalimumab-aaty) injection

Approval Date: May 2023

Note: New Product

A biosimilar to Humira (adalimumab) this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis

Paxlovid (nirmatrelvir and ritonavir) tablets

Approval Date: May 2023

Note: New Product

Indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19

Inpefa (sotagliflozin) tablets

Approval Date: May 2023

Note: New Product

Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes

Opvee® (nalmefene hydrochloride) nasal spray

Approval Date: May 2023

Note: New Product

Indicated for the emergency treatment of known or suspected opioid overdose. This is the first approval of nalmefene hydrochloride nasal spray for health care and community use

Brixadi (buprenorphine) extended-release injection

Approval Date: May 2023

Note: New Product

Indicated for the treatment of moderate to severe opioid use disorder (OUD). Brixadi is administered in a healthcare setting and is available in weekly or monthly formulations, each at various dosages

Motpoly XR (lacosamide)

Approval Date: May 2023

Note: New Product

Indicated for the treatment of partial-onset seizures in adults

Abilify Asimtufii® (aripiprazole)

Approval Date: Apr 2023

Note: New Formulation

Indicated for the treatment of schizophrenia or as maintenance monotherapy treatment of bipolar I disorder

Uzedy (risperidone) extended-release injectable suspension

Approval Date: Apr 2023

Note: New Formulation

Indicated for the treatment of schizophrenia in adults

Zavzpret (zavegepant) nasal spray

Approval Date: Mar 2023

Note: New Product

Indicated for the acute treatment of migraine with or without aura

Combogesic® (acetaminophen and ibuprofen) tablets

Approval Date: Mar 2023

Note: New Product

Indicated for the short term management of mild to moderate acute pain

Trokendi XR (topiramate) extended-release capsules

Approval Date: Feb 2023

Note: First-Time Generic

Indicated for the treatment of partial-onset or primary generalized tonic-clonic seizures, adjunctive therapy for partial-onset, primary generalized tonic-clonic seizures, seizures associated with Lennox-Gastaut syndrome (LGS), and preventive treatment of migraine

Advil Dual Action (acetaminophen and ibuprofen) tablets (OTC)

Approval Date: Feb 2023

Note: First-Time Generic

Temporarily relieves minor aches and pains due to headache, toothache, backache, menstrual cramps, muscular aches, minor pain of arthritis

Leqembi (lecnemab-irmb) injection

Approval Date: Jan 2023

Note: New Product

Indicated for the treatment of Alzheimer’s in patients with mild cognitive impairment or mild dementia sage of the disease

Sunlenca® (lenacapavir) tablets

Approval Date: Dec 2022

Note: New Product

In combination with other antiretrovirals, this drugs is indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection

Idacio® (adalimumab-aacf) injection

Approval Date: Dec 2022

Note: New Product

Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis

1 2 3

Medication Name

Approval Date

Category

Description

Otulfi™ (ustekinumab-aauz)

Sep 2024

A biosimilar to Stelara, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

Note: New Product

Zurnai® (nalmefene injection)

Aug 2024

An opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids.

Note: New Product

Neffy® (epinephrine nasal spray)

Aug 2024

Indicated for the emergency treatment of type I allergic reactions, including anaphylaxis

Note: New Product

Tezruly™ (terazosin) oral solution

Jul 2024

Indicated for the treatment of hypertension alone or with other antihypertensive agents, and for the treatment of enlarged prostate

Note: New Product

Zunveyl (benzgalantamine) delayed-release tablets

Jul 2024

Indicated for the treatment of mild to moderate dementia of the Alzheimer's type

Note: New Product

Olumiant (baricitinib) tablets

Jul 2024

Indicated for the treatment of moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers

Note: First-Time Generic

Kisunla (donanemab-azbt) injection

Jul 2024

Indicated for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patient with mild cognitive impairment or mild dementia stage of disease, the population in which the treatment was initiated in the clinical trials

Note: New Product

Qsymia® (phentermine and topiramate) extended-release tablets

Jun 2024

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management

Note: First-Time Generic

Stendra® (avanafil) tablets

Jun 2024

Indicated for the treatment of erectile dysfunction

Note: First-Time Generic

Pyzchiva® (Ustekinumab-ttwe) injection

Jun 2024

A biosimilar to Stelara; indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis

Note: Biosimilar

Chewtadzy (tadalafil) chewable tablets

Jun 2024

A new chewable tablet indicated for the treatment of erectile dysfunction, and the signs and symptoms of benign prostatic hyperplasia

Note: New Product

Descovy® (emtricitabine and tenofovir alafenamide) tablets

May 2024

Indicated for the treatment of HIV-1 infection, in combination with other antiretroviral agents

Note: First-Time Generic

Entresto® (sacubitril and valsartan) tablets

May 2024

Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure

Note: First-Time Generic

Rezenopy (naloxone hydrochloride) nasal spray

Apr 2024

Indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression

Note: New Product

Selarsdi (Ustekinumab-aekn) injection

Apr 2024

A biosimilar of Stelara®, this drug is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis

Note: Biosimilar, New Product

Risvan® (risperidone) for extended-release injectable suspension

Mar 2024

A long-acting, atypical antipsychotic indicated for the treatment of schizophrenia

Note: New Product

Winrevair (sotatercept-csrk) injections

Mar 2024

A first-in-class biologic indicated for the treatment of pulmonary arterial hypertension to increase exercise capacity and reduce the risk of clinical worsening events

Note: Biologic, New Product

Opsynvi® (macitentan and tadalafil) tablets

Mar 2024

Indicated for the treatment of pulmonary arterial hypertension, both in patients who are treatment naïve or who are already on an ERA, PDE5 inhibitor or both

Note: New Product

Tryvio (aprocitentan) tablets

Mar 2024

Indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower blood pressure

Note: New Product

Simlandi® (adalimumab-ryvk) injection

Feb 2024

A biosimilar to Humira, this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, and plaque psoriasis

Note: Biosimilar

Tybost (cobicistat) tablets

Feb 2024

Indicated for the treatment of HIV-1 infection

Note: First-Time Generic

Dilaudid (hydromorphone hydrochloride) injection

Feb 2024

Indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate

Note: First-Time Generic

Namzaric® (memantine and donepezil hydrochloride) extended release capsules

Dec 2023

Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily

Note: First-Time Generic

Zepbound (tirzepatide) injection

Nov 2023

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity

Note: New Product

Zituvimet (sitagliptin and metformin hydrochloride) tablets

Nov 2023

Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes

Note: New Product

Voquezna (vonoprazan fumarate) tablets

Nov 2023

Indicated for erosive esophagitis and the relief of heartburn associated with erosive esophagitis

Note: New Product

Zymfentra (infliximab-dyyb) injection

Oct 2023

Indicated for the maintenance treatment of moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, following treatment with an infliximab product administered intravenously

Note: New Product

Omvoh (mirikizumab-mrkz) injection

Oct 2023

A first-in-class agent indicated for the treatment of moderate to severe ulcerative colitis

Note: New Product

Wezlana (ustekinumab-auub) injection

Oct 2023

A biosimilar to Stelara, indicated for the treatment of moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

Note: Biosimilar

Velsipity (estrasimod) tablets

Oct 2023

Indicated for the treatment of moderate to severe ulcerative colitis

Note: New Product

Cosentyx® (secukinumab) injection for intravenous use

Oct 2023

Indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions, this drug is now available in an intravenous formulation

Note: New Dosage or Formulation

Bimzelx® (bimekizumab-bkzx) injection for subcutaneous use

Oct 2023

Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Note: New Product

Combogesic® IV (acetaminophen and ibuprofen)

Oct 2023

Indicated for the short term management of mild to moderate acute pain, and the management of moderate to severe pain as an adjunct to opioid analgesics, this drug is now available in an intravenous formulation

Note: Dosage or Formulation

Tofidence (tocilizumab-bavi) injection 

Sep 2023

Indicated for the treatment of rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs)

Note: New Product

Xeljanz (tofacitinib) oral solution

Sep 2023

Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis

Note: First-Time Generic

Exxua (gepirone) extended-release tablets

Sep 2023

Indicated for the treatment of major depressive disorder (MDD), a first-in-class drug that selectively targets the serotonin 1A receptor

Note: New Product

Lexette (halobetasol propionate) topical foam

Aug 2023

Indicated for the topical treatment of plaque psoriasis

Note: First-Time Generic

Onglyza (saxagliptin) tablets

Jul 2023

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Note: First-Time Generic

Kombiglyze® XR (saxagliptin and metformin hydrochloride) extended-release tablets

Jul 2023

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate

Note: First-Time Generic

RiVive (naloxone hydrochloride) nasal spray

Jul 2023

Indicated for the emergency treatment of known or suspected opioid overdose, this drug is the second over-the-counter nonprescription opioid overdose drug approved by the FDA

Note: New Product

Spiriva® HandiHaler (tiotropium bromide) inhalation powder

Jun 2023

For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Note: First-Time Generic

Katerzia® (amlodipine benzoate) oral suspension

Jun 2023

For the treatment of hypertension and coronary artery disease

Note: First-Time Generic

Fleqsuvy (baclofen) oral suspension

Jun 2023

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

Note: First-Time Generic

Diastat® AcuDial (diazepam) rectal gel delivery system

May 2023

Indicated for the management of selected, refractory, patients with epilepsy, on stable regimens of anti-epileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity

Note: First-Time Generic

Celontin® (methsuximide) capsules

May 2023

Indicated for the control of absence (petit mal) seizures that are refractory to other drugs

Note: First-Time Generic

Yuflyma (adalimumab-aaty) injection

May 2023

A biosimilar to Humira (adalimumab) this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis

Note: New Product

Paxlovid (nirmatrelvir and ritonavir) tablets

May 2023

Indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19

Note: New Product

Inpefa (sotagliflozin) tablets

May 2023

Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes

Note: New Product

Opvee® (nalmefene hydrochloride) nasal spray

May 2023

Indicated for the emergency treatment of known or suspected opioid overdose. This is the first approval of nalmefene hydrochloride nasal spray for health care and community use

Note: New Product

Brixadi (buprenorphine) extended-release injection

May 2023

Indicated for the treatment of moderate to severe opioid use disorder (OUD). Brixadi is administered in a healthcare setting and is available in weekly or monthly formulations, each at various dosages

Note: New Product

Motpoly XR (lacosamide)

May 2023

Indicated for the treatment of partial-onset seizures in adults

Note: New Product

Abilify Asimtufii® (aripiprazole)

Apr 2023

Indicated for the treatment of schizophrenia or as maintenance monotherapy treatment of bipolar I disorder

Note: New Formulation

Uzedy (risperidone) extended-release injectable suspension

Apr 2023

Indicated for the treatment of schizophrenia in adults

Note: New Formulation

Zavzpret (zavegepant) nasal spray

Mar 2023

Indicated for the acute treatment of migraine with or without aura

Note: New Product

Combogesic® (acetaminophen and ibuprofen) tablets

Mar 2023

Indicated for the short term management of mild to moderate acute pain

Note: New Product

Trokendi XR (topiramate) extended-release capsules

Feb 2023

Indicated for the treatment of partial-onset or primary generalized tonic-clonic seizures, adjunctive therapy for partial-onset, primary generalized tonic-clonic seizures, seizures associated with Lennox-Gastaut syndrome (LGS), and preventive treatment of migraine

Note: First-Time Generic

Advil Dual Action (acetaminophen and ibuprofen) tablets (OTC)

Feb 2023

Temporarily relieves minor aches and pains due to headache, toothache, backache, menstrual cramps, muscular aches, minor pain of arthritis

Note: First-Time Generic

Leqembi (lecnemab-irmb) injection

Jan 2023

Indicated for the treatment of Alzheimer’s in patients with mild cognitive impairment or mild dementia sage of the disease

Note: New Product

Sunlenca® (lenacapavir) tablets

Dec 2022

In combination with other antiretrovirals, this drugs is indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection

Note: New Product

Idacio® (adalimumab-aacf) injection

Dec 2022

Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis

Note: New Product
1 2 3
lockenvelopephone-handsetmagnifiermenucross-circle